1. Introduction
===============

*Peperomia dindygulensis* Miq. (Piperaceae), a widespread herb in the south of China, is used in the folk medicine to treat cough, asthma, phthisis, and stomach, lung, mammary and liver cancers \[[@B1-molecules-17-04474]\]. The common constituents of *Peperomia* genus include secolignans, tetrahydrofuran lignans, chromones and acylcyclohexane-1,3-diones \[[@B2-molecules-17-04474],[@B3-molecules-17-04474],[@B4-molecules-17-04474],[@B5-molecules-17-04474],[@B6-molecules-17-04474],[@B7-molecules-17-04474]\], which possess various bioactivities, such as antitumor and anti-HIV activities \[[@B8-molecules-17-04474]\]. We found that the chloroform extract prepared from *P. dindygulensis* showed significant suppression acitivity against the proliferation of primary human umbilical vein endothelial cells (HUVEC). In our previous research, we isolated some antiangiogenic secolignans including two new secolignans from *P. dindygulensis* \[[@B9-molecules-17-04474]\]. Further fractionation and purification of the CHCl~3~ extract led to the isolation and characterization of two new polyketides: 2-(heptadec-12-enyl)-4-hydroxy-3,4,7,8- tetrahydro-*2H*-chromen-5(*6H*)-one (**1**) and 2-(heptadec-12-enyl)-5-hydroxy-5,6,7,8-tetrahydrochromen-4- one (**2**), together with eleven known compounds: 4-hydroxy-2-\[(3,4-methylenedioxyphenyl)tridecanoyl\] cyclohexane-1,3-dione (**3**) \[[@B10-molecules-17-04474]\], oleiferinone (**4**) \[[@B11-molecules-17-04474]\], 4-hydroxy-2-\[(3,4-methylenedioxyphenyl) undecanoyl\]cyclohexane-1,3-dione (**5**) \[[@B10-molecules-17-04474]\], 4-hydroxy-2-\[(11-phenylundecanoyl)cyclohexane-1,3-dione (**6**) \[[@B12-molecules-17-04474]\], proctorione C (**7**) \[[@B13-molecules-17-04474]\], surinone C (**8**) \[[@B14-molecules-17-04474]\], 5-hydroxy-7,8,4\'-trimethoxyflavone (**9**) \[[@B15-molecules-17-04474]\], 5-hydroxy-7,8,3\',4\'-tetramethoxyflavone (**10**) \[[@B16-molecules-17-04474]\], 5-hydroxy-7,3\',4\'-trimethoxyflavone (**11**) \[[@B17-molecules-17-04474]\], 5,8-dihydroxy-7,3\',4\'-trimethoxyflavone (**12**) \[[@B15-molecules-17-04474]\] and cepharanone B (**13**) \[[@B18-molecules-17-04474]\] ([Figure 1](#molecules-17-04474-f001){ref-type="fig"}).

![Structures of compounds **1**--**13**.](molecules-17-04474-g001){#molecules-17-04474-f001}

2. Results and Discussion
=========================

Compound **1** was assigned the molecular formula C~26~H~44~O~3~ from the HRESI-MS *m/z*427.3185 \[M+Na\]^+^ peak (calcd for C~26~H~44~O~3~Na, 427.3188). The IR spectrum exhibited a hydroxyl absorption at 3,466 cm^−1^. A long alkyl chain was indicated from the multiple-proton signal in the range *δ*~H~ 1.26--1.37 in the ^1^H-NMR spectrum ([Table 1](#molecules-17-04474-t001){ref-type="table"}). Two olefinic signals at *δ*~C~ 129.8 and 129.9 in the ^13^C-NMR spectrum ([Table 1](#molecules-17-04474-t001){ref-type="table"}) suggested the presence of a double bond, and its position at C-12\' was further confirmed by EI-MS ([Figure 2](#molecules-17-04474-f002){ref-type="fig"}), HMBC and ^1^H-^1^H COSY spectra ([Figure 3](#molecules-17-04474-f003){ref-type="fig"}). The *cis*-geometry of a double bond could be deduced from chemical shifts of C-11\' (*δ*~C~ 27.2) and C-14\' (*δ*~C~ 26.9) \[[@B19-molecules-17-04474]\]. Two oxymethine \[*δ*~H~ 4.00 (1H, *dddd*, 1.7, 5.4, 7.3,11.2, H-2) and *δ*~H~ 4.75 (1H, *dd*, 7.0, 9.3, H-4)\] and five methylenes \[*δ*~H~ 2.22 (1H, *ddd*, 2.0, 6.7, 13.5, H-3a) and 1.70 (1H, *m*, H-3b), *δ*~H~ 2.33 (1H, *dd*, 9.6, 16.8, H-6a) and 2.39 (1H, *m*, H-6b), *δ*~H~ 1.97 (1H, *dd*, *J*= 6.3, 12.9, H-7a) and 1.96 (1H, *dd*, *J*= 6.1, 12.9, H-7b), *δ*~H~ 2.40 (2H, *m*, H-8), *δ*~H~ 1.62 (1H, *m*, H-1\'a) and 1.73 (1H, *m*, H-1\'b)\] were found to be connected to two moieties, ^6^CH~2~--^7^CH~2~--^8^CH~2~ and O--^4^CH--^3^CH~2~--^2^CH(O)--^1\'^CH~2~ using the ^1^H--^1^H COSY spectrum. The above two moieties were linked by the two quaternary olefinic carbons *δ*~C~ 173.4 (C-8a) and 114.7 (C-4a) which showed HMBC cross-peaks with H-4, H-7, H-8, and with H-3, H-8, respectively. The location of carbonyl carbon *δ*~C~ 200.6 (C-5) could be confirmed by the HMBC correlations with H-6 and H-7. Thus, the moiety were determined as O=^5^C--^6^CH~2~--^7^CH~2~--^8^CH~2~--^8a^C=^4a^C--^4^CH(O)--^3^CH~2~--^2^CH(O)--^1\'^CH~2~ and further confirmed by the homoallylic coupling between H-4 and H-8 in the ^1^H-^1^H COSY spectrum. The downfield chemical shift of C-8a and the remaining two degrees of unsaturation suggested that the oxygen at C-2 connected to C-8a, and C-5 to C-4a. The 5-hydroxytetrahydrochromen moiety was also confirmed by the mass spectrum which showed a fragment at *m/z*167 ([Figure 2](#molecules-17-04474-f002){ref-type="fig"}). Thus, the structure of **1** was elucidated as 2Z-(heptadec-12-enyl)-4-hydroxy-3,4,7,8-tetrahydro-*2H*-chromen-5(*6H*)-one. The NOE correlation between H-2 and H-4 indicated their *cis*-configuration.

molecules-17-04474-t001_Table 1

###### 

^1^H- (400 MHz) and ^13^C-NMR (100 MHz) data of compound **1** (in CDCl~3~; *δ* in ppm, *J* in Hz).

  Position     δ~C~           δ~H~
  ------------ -------------- --------------------------------------------------------
  2            77.1           4.00 (1H, *dddd*, 1.7, 5.4, 7.3,11.2)
  3            35.2           2.22 (1H, *ddd*,2.0, 6.7, 13.5); 1.70 (1H, *m*)
  4            62.1           4.75 (1H, *dd*, 7.0, 9.3)
  4a           114.7          
  5            200.6          
  6            36.7           2.33 (1H, *dd*, 9.6, 16.8); 2.39 (1H, *m*)
  7            20.5           1.97 (1H, *dd*, 6.3, 12.9); 1.96 (1H, *dd*, 6.1, 12.9)
  8            28.4           2.40 (2H, *m*)
  8a           173.4          
  1\'          34.7           1.62 (1H, *m*); 1.73 (1H, *m*)
  2\'          25.0           1.46 (2H, *m*)
  3\'-10\'     29.3--29.8     1.26--1.37 (16H, *m*)
  11\'         27.2           2.00 (2H, *m*)
  12\', 13\'   129.8, 129.9   5.35 (2H, *m*)
  14\'         26.9           2.01 (2H, *m*)
  15\'         32.0           1.30 (2H, *m*)
  16\'         22.4           1.31 (2H, *m*)
  17\'         14.0           0.88 (3H, *t*, 7.0)
  OH-4                        4.63 ( *brs*)

![MS fragmentation of **1**.](molecules-17-04474-g002){#molecules-17-04474-f002}

![Key ^1^H-^1^H COSY and HMBC correlations of **1**.](molecules-17-04474-g003){#molecules-17-04474-f003}

Compound **2** had the molecular formula C~26~H~42~O~3~ as deduced from the HRESI-MS peak at *m/z*425.3029 \[M+Na\]^+^ (calcd for C~26~H~42~O~3~Na, 425.3032). The UV maxima at 249 nm, and the IR absorptions at 1,661, 1,605 cm^−1^ suggested the presence of a γ-pyrone ring, which was 2,3,5-trisubstituted according to the olefinic signals at *δ*~C~ 112.7 (C-3) and *δ*~H~ 6.10 (1H, s, H-3) in the NMR spectra ([Table 2](#molecules-17-04474-t002){ref-type="table"}) \[[@B20-molecules-17-04474]\]. Similar to compound **1**, it showed evidence for one moiety, ^5^CH(O)--^6^CH~2~--^7^CH~2~--^8^CH~2~, and a alkyl chain from the ^1^H-NMR, ^13^C-NMR, and ^1^H-^1^H COSY and HMBC spectra ([Figure 4](#molecules-17-04474-f004){ref-type="fig"}). In the HMBC spectrum, the proton of the oxymethylene *δ*~H~ 4.91 (1H, *br t*, *J*= 3.8 Hz, H-5) showed correlation with the carbonyl carbon (*δ*~C~ 180.7), C-4a (*δ*~C~ 123.2), C-6 (*δ*~C~ 29.5), C-7 (*δ*~C~ 18.1) and C-8 (*δ*~C~ 27.6), indicating that C-5 is connected with C-4a. The protons of the methylene \[*δ*~H~ 2.46 (1H, *m*, H-8a) and 1.98 (1H, *m*, H-8b)\] gave cross peaks with the carbons at C-5, C-6, C-7, C-4a and C-8a, but not with C-4, suggesting that C-8 is attached to C-8a. Surprisingly, the weak four bond reciprocal H-5/C-8 and H-8/C-5 HMBC correlations signals were observed. Although these may be considered unusual, such long-range correlations have been reported, especially in constrained ring systems \[[@B21-molecules-17-04474],[@B22-molecules-17-04474],[@B23-molecules-17-04474]\]. The HMBC spectrum also suggested the linkage of C-2 and the alkyl chain. Thus, the structure of **2** was determined to be 2-(heptadec-12-enyl)-5-hydroxy-5,6,7,8- tetrahydrochromen-4-one.

molecules-17-04474-t002_Table 2

###### 

^1^H- (400 MHz) and ^13^C-NMR (100 MHz) data of compound **2**(in CDCl~3~; *δ* in ppm, *J* in Hz).

  Position     δ~C~         δ~H~
  ------------ ------------ --------------------------------
  2            169.3        
  3            112.7        6.10 (1H, *s*)
  4            180.7        
  4a           123.2        
  5            63.8         4.91 (1H, *br t*, 3.8)
  6            29.5         1.76 (1H, *m*); 1.96 (1H, *m*)
  7            18.1         1.74 (1H, *m*); 1.97 (1H, *m*)
  8            27.6         2.49 (1H, *m*); 2.57 (1H, *m*)
  8a           165.0        
  1\'          33.5         2.48 (2H, *t*, 7.6)
  2\'          26.8         1.61 (2H, *m*)
  3\'--10\'    28.9--29.7   1.26--1.37 (16H, *m*)
  11\'         27.1         2.00 (2H, *m*)
  12\', 13\'   129.8        5.35 (2H, *m*)
  14\'         26.9         2.01 (2H, *m*)
  15\'         31.9         1.30 (2H, *m*)
  16\'         22.3         1.31 (2H, *m*)
  17\'         14.0         0.89 (3H, *t*, 6.4)
  5-OH                      4.43 ( *br*s)

![Key ^1^H-^1^H COSY and HMBC correlations of **2**.](molecules-17-04474-g004){#molecules-17-04474-f004}

The structures of known compounds **3**\~**13** were confirmed by detailed NMR and MS data comparison with those in the literature \[[@B10-molecules-17-04474],[@B11-molecules-17-04474],[@B12-molecules-17-04474],[@B13-molecules-17-04474],[@B14-molecules-17-04474],[@B15-molecules-17-04474],[@B16-molecules-17-04474],[@B17-molecules-17-04474],[@B18-molecules-17-04474]\]. In addition, some similar compounds have been reported from *Trichoderma* \[[@B24-molecules-17-04474],[@B25-molecules-17-04474]\].

*In vitro* cytotoxicity of all the isolated compounds to HUVEC was examined after 48 h incubation. It was found that compounds **2**, **3**, **5**, **8** could dose dependently induced significant toxicity to HUVEC at different concentrations ([Figure 5](#molecules-17-04474-f005){ref-type="fig"}). The growth of HUVEC was almost completely inhibited by compound **3** at 24 μM. Compounds **5** and **8** also exhibited significant tube formation-inhibiting activity at 3, 6, 12 and 24 μM, respectively ([Figure 6](#molecules-17-04474-f006){ref-type="fig"}).

![Effect of compounds **2** (**A**), **3** (**B**), **5** (**C**), **8** (**D**) on the viability of HUVEC after 48 h incubation. For blank control, the DMSO concentration was adjusted to below 0.1%. Values are expressed as mean ± SD, n = 4--6. \* *p* \< 0.05, \*\* *p* \< 0.01 as compared with control.](molecules-17-04474-g005){#molecules-17-04474-f005}

![Effect of compounds **5**, compound **8**, and ursolic acid on HUVEC tube formation. **A**, **B**, and **C**: Tube length (% of control) after treatment with compound **5**, compound **8**, and ursolic acid (positive control), respectively. Values are expressed as mean ± SD, n = 4. \* *p*\< 0.05, \*\* *p*\< 0.01 as compared with control. (**D**): The representative photographs of tube networks after treatment with ursolic acid (10 μM) and compounds **5** and **8** at various concentrations. Bar = 200 μm.](molecules-17-04474-g006){#molecules-17-04474-f006}

3. Experimental
===============

3.1. General
------------

Optical rotations were measured on a Perkin-Elmer 341 polarimeter. UV spectra were recorded on a Shimadzu UV-2500 PC spectrophotometer. IR spectra were recorded on a Nexus 670 spectrometer. NMR spectra were measured on a Bruker DRX 400 spectrometer and Bruker AV 500 spectrometer. EI-MS (70 eV) was carried out on an Autospec Premier P708 mass spectrometer. ESI-MS was carried out on a Waters Q-Tof micro YA019 mass spectrometer. Silica gel (200--300 mesh) was used for column chromatography, and pre-coated silica gel GF254 plates (Qingdao Marin Chemical Plant, Qingdao, China) were used for TLC.

3.2. Plant Material
-------------------

*Peperomia dindygulensis* Miq., collected in Simao Region Yunnan Province of China in June 2008, was identified by Associate Professor Guo-Hong Yang. A voucher specimen (GHY-PDM20080728) has been deposited in the Herbarium of the Laboratory of Department of Traditional Chinese Medicine, Shanghai Institute of Pharmaceutical Industry, China.

3.3. Extraction and Isolation
-----------------------------

The air-dried whole plant (10 kg) of *P. dindygulensis*was extracted exhaustively with 95% EtOH at r.t. (250 L, 7 days). The EtOH extract was evaporated *in vacuo* to yield a semisolid (1,300 g), of which 1,290 g was suspended in H~2~O (2,000 mL) and partitioned with CHCl~3~ (2,000 mL × 5) to yield 756 g of extract after concentration. Part of the CHCl~3~ extract (300 g) was subjected to column chromatography on Si gel (200\~300 mesh, 3 kg) eluted with petroleum ether/EtOAc (100:0, 99:1, 49:1, 19:1, 9:1, 4:1, 7:3, 3:2, 1:1) and EtOAc to yield ten fractions (Frs. **1**--**10**). Fraction **6** (13.9 g) was separated repeatedly on silica gel columns (5 × 50 cm) using *n*-hexane/acetone (5:1) as eluent to obtain six fractions (**6A**--**F**). Fraction **6B** (227 mg) was further purified by Sephadex LH-20 and eluted with CHCl~3~/MeOH (1:1) to give **1** (10 mg). Fraction **6D** (139 mg) was purified repeatedly by Sephadex LH-20 using CHCl~3~/MeOH (1:1) as eluent to give **3** (20 mg). Fraction **7** (21.8 g) was separated repeatedly on silica gel columns (5 × 50 cm) using *n*-hexane/acetone (4:1) as eluent to obtain five fractions (**7A**--**E**). Fraction **7B** (1.6 g) was further purified by Sephadex LH-20 \[eluted with CHCl~3~/MeOH (1:1)\] to give four fractions, and the second fraction (700 mg) was applied to preparative silica gel TLC using *n*-hexane/acetone/acetic acid (5:1:0.1) as eluent to afford **4** (40 mg), **5** (100 mg) and **6** (12 mg). Fraction **7C** (7.6 g) was chromatographed over silica gel columns (3 × 50 cm) and eluted with *n*-hexane/EtOAc (3:1) to obtain five fractions, the second fraction (154 mg) was applied to preparative silica gel TLC using toluene/EtOAc (9:1) as eluent to give **11** (4 mg). Fraction **8** (4.5 g) was chromatographed over silica gel columns (3 × 50 cm) eluted with CHCl~3~/MeOH (50:1) to obtain four fractions (**8A**--**D**). Fraction **8B** (205 mg) was recrystallized from CHCl~3~/MeOH (1:1) to afford **9** (51 mg). Fraction **8C** (600 mg) was recrystallized from CHCl~3~/MeOH (1:1) to afford **10** (246 mg). Fraction **8D** (1.4 g) was chromatographed over silica gel columns (3 × 50 cm) and eluted with *n*-hexane/acetone/acetic acid (100:10:1) to give **2** (277 mg) and **6** (36 mg). Fraction **9** (18.9 g) was separated repeatedly on silica gel columns (5 × 50 cm) using n-hexane/acetone (4:1) as eluent to obtain eight fractions (**9A**--**H**). Fraction **9B** (1.5 g) was further separated repeatedly on silica columns (3 × 50 cm) and eluted with CHCl~3~/acetone (200:1) to give three fractions, and the second fraction was subjected to preparative silica gel TLC using *n*-hexane/acetone/acetic acid (100:10:1) as eluent to give **8** (20 mg). Fraction **9D** (1.8 g) was chromatographed on silica gel columns (3 × 50 cm) using *n*-hexane/acetone (5:1) as eluent to obtain three fractions, and the last fraction (222 mg) was further purified by Sephadex LH-20 and eluted with CHCl~3~/MeOH (1:1) to give **13** (5 mg). Fraction **9E** (12.2 g) was separated repeatedly on silica gel columns (5 × 50 cm) using CHCl~3~ as eluent to obtain six fractions, and the last fraction was separated repeatedly by Sephadex LH-20 and eluted with CHCl~3~/MeOH (1:1) to give **12** (12 mg).

*2Z-(Heptadec-12-enyl)-4-hydroxy-3*,*4*,*7*,*8-tetrahydro-2H-chromen-5(6H)-one* (**1**). Yellowish oil; \[α\]~D~^13^ 126° (c = 0.368, CHCl~3~); UV λ~max~ (MeOH) nm (log ε): 258 (4.44); IR (NaCl) ν~max~: 3466, 2925, 2854, 1613, 1427, 1370, 1249, 1188, 1083, 1054 cm^−1^; EI-MS *m/z*404 \[M\]^+^ (9.1), 386 (100.0), 167 (24.1), 139 (50.7), 125 (43.1), 111(41.9), 97 (5.2), 43 (21.5); ^1^H- and ^13^C-NMR data: see [Table 1](#molecules-17-04474-t001){ref-type="table"}; HRESI-MS *m/z*427.3185(\[*M*+Na\]^+^, calcd for C~26~H~44~O~3~Na 427.3188).

*2-(Heptadec-12-enyl)-5-hydroxy-5*,*6*,*7*,*8-tetrahydrochromen-4-one* (**2**). Yellowish oil; \[α\]~D~^13^ 34° (c = 0.435, CHCl~3~); UV λ~max~ (MeOH) nm (log ε): 216 (3.66), 249 (3.68); IR(NaCl) ν~max~: 3431, 3003, 2926, 2854, 1716, 1661, 1605, 1436, 1176, 1086, 950, 859, 722 cm^−1^; ^1^H- and ^13^C-NMR data: see [Table 2](#molecules-17-04474-t002){ref-type="table"}; HRESI-MS *m/z* 425.3029 (\[*M*+Na\]^+^, calcd for C~26~H~42~O~3~Na 425.3032).

3.4. Antiangiogenic Activity Assays
-----------------------------------

The effect of isolated compounds on the proliferation of HUVEC was evaluated by CCK-8. HUVEC tube formation was conducted for the assay of *in vitro* angiogenesis using the Chemicon *in vitro* angiogenesis assay kit (ECM625). Details of the assays were provided in a previous report \[[@B9-molecules-17-04474]\].

4. Conclusions
==============

Two new polyketides: 2*Z*-(heptadec-12-enyl)-4-hydroxy-3,4,7,8-tetrahydro-*2H*-chromen-5(*6H*)-one (**1**), and 2-(heptadec-12-enyl)-5-hydroxy-5,6,7,8-tetrahydrochromen-4-one (**2**), were isolated from *Peperomia dindygulensis*, together with eleven known compounds **3**--**13**. Compounds **2**, **3**, **5** and **8** inhibited human umbilical vein endothelial cells (HUVEC) proliferation and compounds **5** and **8** sharply suppressed HUVEC tube formation.
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